Potensi Nano Analog RN-18 (NARN-18) Berbasis Nanopartikel PLGA-CS-PEG dalam Penatalaksanaan HIV-1
Abstract
Acquired Immune Deficiency Syndrome (AIDS) is the cause of death of million people in the world in 2016. The prevalence of Human Immunodeficiency Virus-1 (HIV-1) infection in Indonesia is still high and number of death caused by HIV-1-related diseases shows an apprehensive number. Treatment of HIV/AIDS nowadays is not effective to eradicate HIV-1 and also cause adverse effects. Previous research found RN-18 as a specific antagonistic molecule for viral infectivity factor (Vif) that can trigger Vif degradation and maintain intracellular A3G level. The aim of this review is to examine the potential of NARN-18 based PLGA-CS-PEG nanoparticles through oral administration in the management of HIV-1 infection. Method of this article is using literature review method. Literature searching is done by using “A3G”, “HIV-1”, “PLGA-CS-PEG”, “RN-18”, and “Vif” as keywords in search engine. 13a molecule, that is the analogue of RN-18, is used in the modality because it has better effectiveness and solubility compared with RN-18. By using PLGA, PEG, and chitosan (CS) as nanoparticles that carries RN-18 analogue makes the modality can be taken orally and targets T cell as soon as it enters the blood stream. It also can increase the efficiency of drug release and drug loading of the modality. NARN-18 constructed by using PLGA-PEG-CS nanoparticle makes the modality can be administered orally, increase its half-life in the body, and also increase the inhibition effect of RN-18 analogue. Therefore, this combination is one of the potential therapy in HIV-1 infection treatment.
Keywords
Full Text:
PDFReferences
Adolph M, Webb J, dan Chelico L, 2013. Retroviral Restriction Factor APOBEC3G Delays the Initiation of DNA Synthesis by HIV-1 Reverse Transcriptase. PLoS ONE. 8(5): e64196.
Aguilar Z, 2013. Targeted Drug Delivery. Nanomaterials for Medical Applications: 181-234.
Alkie TN, Taha-Abdelaziz K, Barjesteh N, Bavananthasivam J, Hodgins DC and Sharif S, 2017. Characterization of innate responses induced by PLGA encapsulated-and soluble TLR ligands in vitro and in vivo in chickens. PLoS One. 12(1): e0169154.
Andrew A and Strebel K, 2014. HIV-1 Accessory Proteins: Vpu and Vif. Methods Mol Biol. 1087: 135-158.
Armitage AE, Deforche K, Chang CH, Wee W, Kramer B, et al, 2012. APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon. PLoS Genetics. 8(3): e1002550.
Cadima-Couto I and Goncalves J, 2010. Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?. Adv Virol. 2010: 1-10.
Chandra E, Mudhakir D, and Ws AH, 2014. Studi Biodistribusi Dan Farmakokinetik Nanokarier PLGA-Poloxamer Bertanda Radioisotop Iodium-131 Pada Mencit. Research and Development on Nanotechnology in Indonesia. 1(2): 39-47.
Chaurasiya KR, McCauley MJ, Wang W, Qualley DF, Wu T, et al 2013. Oligomerization Transforms Human APOBEC3G From an Efficient Enzyme to a Slowly Dissociating Nucleic Acid-Binding Protein. Nature Chemistry. 6(1): 28-33.
Cimarelli A and Darlix J, 2014. HIV-1 Reverse Transcription. Methods Mol Biol. 1087: 55-70.
Cihlar T, and Ray AS, 2010. Nucleoside and Nucleotide HIV Reverse Transcriptase Inhibitors: 25 Years After Zidovudine. Antiviral Res. 85(1): 39-58.
Collins D and Collins K, 2014. HIV-1 Accessory Proteins Adapt Cellular Adaptors to Facilitate Immune Evasion. PLoS Pathogens. 10(1): e1003851.
Das A, Harwig A and Berkhout B, 2011. The HIV-1 Tat Protein Has a Versatile Role in Activating Viral Transcription. Journal of Virology. 85(18): 9506-9516.
Fairley SJ, Singh SR, Yilma AN, Waffo AB, Subbarayan P, et al, 2013. Chlamydia Trachomatis Recombinant MOMP Encapsulated in PLGA Nanoparticles Triggers Primarily T helper 1 Cellular and Antibody Immune Responses in Mice: a Desirable Candidate Nanovaccine. International Journal of Nanomedicine. 8: 2085-2099.
Desimmie BA, Delviks-Frankenberry KA, Burdick R, Qi D, Izumi T, et al, 2014. Multiple APOBEC3 Restriction Factors for HIV-1 and One Vif to Rule Them All. Journal of molecular biology. 426(6): 1220-1245.
Ebrahimian M, Hashemi M, Maleki M, Abnous K Hashemitabar G, 2016. Induction of a Balanced Th1/Th2 Immune Responses by Co-Delivery of PLGA/Ovalbumin Nanospheres and Cpg Odns/PEI-SWCNT Nanoparticles as TLR9 Agonist in BALB/C Mice. International journal of pharmaceutics. 515(1-2): 708-720.
Engelman A, and Cherepanov P, 2012. The Structural Biology of HIV-1: Mechanistic and Therapeutic Insights. Nature Reviews Microbiology. 10(4): 279-290.
Hajimahdi Z and Zarghi A, 2016. Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity. Iran J Pharm Res. 15(4): 595-628.
Hamdy S, Haddadi A, Shayeganpour A, Samuel J and Lavasanifar A, 2011. Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles. Pharm Res. 28(9): 2288-2301.
Hølvold L, Fredriksen B, Bøgwald J and Dalmo R, 2013. Transgene and Immune Gene Expression Following Intramuscular Injection of Atlantic Salmon (Salmo Salar L.) With DNA-Releasing PLGA Nano-And Microparticles. Fish & shellfish immunology. 35(3): 890-899.
Hu W and Hughes S, 2012. HIV-1 Reverse Transcription. Cold Spring Harb Perspect Med. 2(10): a006882.
Khan N, Jameel J, Jameel N and Rheman S, 2017. An overview: Biosynthesized Nanoparticles with their Potential Applications. Glob J Nano. 2(1): 5-8.
Kobayashi T, Koizumi Y, Takeuchi JS, Misawa N, Kimura Y, et al, 2014. Quantification of Deaminase Activity-Dependent and -Independent Restriction of HIV-1 Replication Mediated by APOBEC3F and APOBEC3G through Experimental-Mathematical Investigation. Journal of Virology. 88(10): 5881-5887.
Kumar A, Vimal A, Kumar A. 2016. Why Kitosan? From properties to Perspective of Mucosal Drug Delivery. Int J Biol Macromol. 91:615–22.
Li J, Mao J, Tang J, Li G, Fang F, et al, 2017. Surface Spermidine Functionalized Pegylated Poly(Lactide-Co-Glycolide) Nanoparticles for Tumor-Targeted Drug Delivery. RSC Advances. 7(37): 22954-22963.
Lucas S dan Nelson A, 2014. HIV and the Spectrum of Human Disease. The Journal of Pathology. 235(2): 229-241.
Maartens G, Celum C, Lewin SR, 2014. HIV Infection: Epidemiology, Pathogenesis, Treatment, and Prevention. The Lancet. 384(9989): 258-271.
Madani N and Kabat D, 2000. Cellular and Viral Specificities of Human Immunodeficiency Virus Type 1 Vif Protein. Journal of virology. 74(13): 5982-5987.
Malatesta M, Grecchi S, Chiesa E, Cisterna B, Costanzo M, et al, 2015. Internalized Chitosan Nanoparticles Persist for Long Time in Cultured Cells. Eur J Histochem. 59(1): 17–21.
Nathans R, Cao H, Sharova N, Ali A, Sharkey M, et al, 2008. Small-molecule Inhibition of HIV-1 Vif. Nature Biotechnology. 26(10): 1187-1192.
Neeta MM, Satija S, Pandey P, and Dahiya M, 2016. Relevance of Ionotropic Gelation Technique in the Development of Floating Multiparticulate Drug Delivery Systems. Int J Adv Sci Research. 1(4): 54-59.
Okada A and Iwatani Y, 2016. APOBEC3G-Mediated G-To-A Hypermutation of the HIV-1 Genome: the Missing Link in Antiviral Molecular Mechanisms. Frontiers in microbiology. 7: 2027.
Parveen S and Sahoo S, 2011. Long Circulating Chitosan/PEG Blended PLGA Nanoparticle for Tumor Drug Delivery. European Journal of Pharmacology. 670(2-3): 372-383.
Rafiei P and Haddadi A, 2017. Docetaxel-loaded PLGA and PLGA-PEG Nanoparticles for Intravenous Application: pharmacokinetics and biodistribution profile. Int J of Nanomedicine. 12: 935-947.
Rawson J, Landman S, Reilly C and Mansky L, 2015. HIV-1 and HIV-2 Exhibit Similar Mutation Frequencies and Spectra in the Absence of G-to-A Hypermutation. Retrovirology. 12(1): 60
Sarti F, Perera G, Hintzen F, Kotti K, Karageorgiou V, et al, 2011. In Vivo Evidence of Oral Vaccination with PLGA Nanoparticles Containing the Immunostimulant Monophosphoryl Lipid A. Biomaterials. 32(16): 4052-4057.
Seitz R, 2016. Human Immunodeficiency Virus (HIV). Transfusion Medicine and Hemotherapy. 43(3): 203-222.
Sharma A, Vora R, Modi M, Sharma A, and Marfatia Y, 2008. Adverse effects of Antiretroviral Treatment. Indian J Dermatol Venereol Leprol. 74(3): 234-237.
Sheehy AM, Gaddis NC, Choi JD, Malim MH, 2002. Isolation of a Human Gene that Inhibits HIV-1 Infection and is Suppressed by the Viral Vif Protein. Nature. 418(6898): 646-650.
Simon V, Bloch N and Landau N, 2015. Intrinsic Host Restrictions to HIV-1 and Mechanisms of Viral Escape. Nature Immunology. 16(6): 546-553.
Taamalli A, Contreras MDM, Abu-Reidah, IM, Trabelsi N, and Ben Youssef N, 2019. Quality of Phenolic Compounds: Occurrence, Health Benefits, and Applications in Food Industry. Journal of Food Quality. 2019.
The Joint United Nations Programme on HIV/AIDS (UNAIDS), 2019. Indonesia. https://www.unaids.org/en/regionscountries/countries/indonesia
Usach I, Melis V and Peris JE, 2013. Non‐Nucleoside Reverse Transcriptase Inhibitors: A Review on Pharmacokinetics, Pharmacodynamics, Safety and Tolerability. Journal of the International AIDS Society. 16(1): 18567.
Wang X, Ao Z, Chen L, Kobinger G, Peng J, et al, 2012. The Cellular Antiviral Protein APOBEC3G Interacts with HIV-1 Reverse Transcriptase and Inhibits its Function during Viral Replication. Journal of Virology. 86(7): 3777-3786.
Wang Z, Wakae K, Kitamura K, Aoyama S, Liu G, et al, 2013. APOBEC3 Deaminases Induce Hypermutation in Human Papillomavirus 16 DNA upon Beta Interferon Stimulation. Journal of Virology. 88(2): 1308-1317.
Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA et al, 2013. Uracil DNA Glycosylase Initiates Degradation Of HIV-1 Cdna Containing Misincorporated Dutp and Prevents Viral Integration. PNAS. 110(6): E448-E457.
Wensing A, van Maarseveen N, and Nijhuis M, 2010. Fifteen Years of HIV Protease Inhibitors: Raising the Barrier to Resistance. Antiviral Research. 85(1): 59-74.
Wilen C, Tilton J, and Doms R, 2012. HIV: Cell Binding and Entry. Cold Spring Harbor Perspectives in Medicine. 2(8): a006866-a006866.
Wu G, Zhou F, Ge L, Liu X and Kong F, 2012. Novel Mannan-PEG-PE Modified Bioadhesive PLGA Nanoparticles for Targeted Gene Delivery. Journal of Nanomaterials. 2012(11): 1-9.
Yeh T, Hsu L, Tseng M, Lee P, Sonjae K, Ho Y and Sung H, 2011. Mechanism and Consequence of Chitosan-mediated Reversible Epithelial Tight Junction Opening. Biomaterials. 32(26): 6164-6173.
Zhang J, Zhu X, Jin Y, Shan W and Huang Y, 2014. Mechanism Study of Cellular Uptake and Tight Junction Opening Mediated by Goblet Cell-Specific Trimethyl Chitosan Nanoparticles. Molecular Pharmaceutics. 11(5): 1520-1532.
Zhao R and Bukrinsky M, 2014. HIV-1 Accessory Proteins: VpR. Methods Mol Biol. 1087: 125-134.
Zhou M, 2017. Synthesis, Biological Evaluation and Molecular Docking Study of N -(2-Methoxyphenyl)-6-((4-Nitrophenyl)Sulfonyl) Benzamide Derivatives as Potent HIV-1 Vif Antagonists. Eur J Med Chem. 129: 310-324.
DOI: http://dx.doi.org/10.30742/jikw.v9i2.864
Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Gede Setula Narayana, I Kadek Wahyu Putra Dyatmika, Widia Danis Swari, I Gede Putu Supadmanaba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Jurnal Ilmiah Kedokteran Wijaya Kusuma is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
